786.9000 4.10 (0.52%)
NSE Oct 29, 2026 09:35 AM
Volume: 4,251
 

Deven Choksey
We maintain a positive FY26E outlook, expecting sustained double-digit growth across US, Ex-US, and RoW businesses. Growth across regions will be majorly driven by a healthy US pipeline, strategic expansion in RoW, and improved execution across India.
Alembic Pharmaceutic.. has an average target of 913.50 from 4 brokers.
More from Alembic Pharmaceuticals Ltd.
Recommended